The National Institutes of Health (NIH) has approved CureVax VxS REV-ERB. NI on July 25th to produce 300 million doses of its curing platform through its pooled funding program.
The Framework for Clinical Trials Network an initiative of the NIH has helped to drive the company into over a quarter of a billion dollars led by the CEO and co-founder of CureVax during the past two years making CureVax the largest member of the network. Under the program CureVax is working to build patients immune systems through the entering of molecules produced by the participants for therapeutic purposes.
CureVax was the first FDA-approved therapeutics for acute lymphoblastic leukemia (ALL) and type 1 non-Hodgkin lymphoma (NHL) in 2017. The company capitalizes on the licensing success of its CRISPR-Cas9 platform by creating a chimeric antigen receptor (CAR) T cell to treat the disease.
Founded and co-founded in 2008 CureVax received regulatory approval of its novel immunotherapy platform earlier this year as part of its continuing clinical development testing strategy.
CureVax developed its immediate family of five distinct T cells which are targeted at various cancers highlighted in the Cancer Center of Excellence Program for human immunodeficiency virus (HIV). In the U. S. the City of Hope-affiliated treatment has been expanded upon to include patient-derived CD4 T cells which are infused back into patients following successful immunotherapy and safely know each other.
About CureVaxFrom the 1800s until the mid-sixties the company focused on molecular diagnostics and treatments to treat cancer and inherited liver diseases. It later became a leading cancer treatment company producing hundreds of millions of doses of CAR-T cells. In July 2020 CureVax rebranded its portfolio to become CureVax Inc. laying out its hybrid treatment strategy in which it combines the advantages of each of its technologies.
This amendment protects CureVaxs unique combination of products that bridge the gap between oncology and immunotherapy. These products include its groundbreaking CAR-T cell therapy which rationally suppresses HIV replication as well as treatments for acute myeloid leukemia (AML) and acute myeloid polyblastocytoma (PMPK) two of the most aggressive forms of childhood cancer. Previously CureVax received two other FDA-declarative consent expansions with the three thecs (including relapsed or refractory clear-stage AML) which provided additional capabilities for its CAM-T cells and CAR-T cells.
In 2016 CureVax partnered with the National Institute of Allergy and Infectious Disease (NIAID) and a Center for Injury Research and Policy Research to explore expansion of its CAR-T cell therapy. A major part of that expansion was the journey to manufacturing patients immune platforms – specially engineered cell lines that can either be used for treating or preventing HIV infection or autoimmune disorders. Currently CureVax is producing immune-modulating CAR-T cells through its cell line repository Cins Exon.
About City of Hope From City of Hope located in Washington D. C. focus on improving the quality of maternal and child health through research education and innovation.
For the past eight years City of Hope has been working to overcome medical challenges and improve the lives of 45000 people and their caregivers through these activities. The Knowlton Family Hospitals Research Institute a private not-for-profit foundation that funds innovative research and innovation in the areas of maternal health and child health is one of the largest non-profit organizations in the United States. In 2019 City of Hope reported earning over 2 billion in total revenue including sales of facilities. City of Hope is a leading player in the intensification of the global opioid epidemic through research that examines a patients opioid use and tolerance factors and the results of treatment using octopamine-progesterone combinations for opioid use disorder.